Schlafen 5 is an intracellular immune checkpoint and controls IFN responses in pancreatic ductal adenocarcinoma

Read full text
Authors: Mariafausta Fischietti, Μαρκέλλα Ζαννίκου, Elspeth M. Beauchamp, Diana Saleiro, Aneta H. Baran, Briana Hryhorysak, Jamie N. Guillen Magaña, Emely Lopez Fajardo, Gavin T. Blyth, Brandyn A. Castro, Jason M. Miska, Catalina Lee-Chang
+5 more Priyam Patel, Elizabeth T. Bartom, Masha Kocherginsky, Frank Eckerdt, Leonidas C. Platanias
Cited by: 0
References: 68

Abstract

We provide evidence that human and murine Schlafen 5 (SLFN5) proteins are modulators of type I IFN responses and the immune response in pancreatic ductal adenocarcinoma (PDAC). Blocking expression of Slfn5 in PDAC enhanced IFN responses, suppressed tumor growth, and prolonged survival in immunocompetent mice. Notably, immunophenotypic analysis revealed a reduction in tumor-associated macrophages alongside an increase in tumor-infiltrating effector cells in tumors over time. These findings suggest SLFN5 acts as an intracellular immune checkpoint and identify it as a unique therapeutic target for the development of therapies for PDAC and possibly other malignancies.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Pancreatic and Hepatic Oncology Research interferon and immune responses

Publication details

Journal / source
JCI Insight
Volume
11
Issue
5
Publication date
27 January 2026
Language
EN